Curocell

Curocell FCF per Share

The Free Cash Flow per Share of Curocell (372320.KQ) as of Oct 27, 2026 is -2,138.16 KRW. In the previous year, Free Cash Flow per Share was -2,086.85 KRW — a change of 2.46% (lower).

FCF per Share

-2,138.16KRW

YoY

2.46%

Last updated:

Free Cash Flow per Share of Curocell is 2025 -2,138.16 KRW. Free Cash Flow per Share of Curocell was 2024 -2,086.85 KRW. It decreases by 2.46% lower compared to the previous year.

The Curocell FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2021
-1,530.58 KRW
Jan 1, 2022
-3,104.56 KRW
Jan 1, 2023
-3,446.36 KRW
Jan 1, 2024
-2,086.85 KRW
Jan 1, 2025
-2,138.16 KRW
The Curocell FCF per Share history
YEARFCF per ShareYoY
-2,138.16KRW+2.46%
-2,086.85KRW-39.45%
-3,446.36KRW+11.01%
-3,104.56KRW+102.84%
-1,530.58KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Curocell Stock analysis

What does Curocell do? Curocell Inc makes money through the development and commercialization of CAR-T therapy technologies for cancer treatment. The company focuses on novel chimeric antigen receptor (CAR)-T therapies targeting specific cancer antigens, improving medicinal effects, reducing side effects, and automating quality analysis. These products are developed for pharmaceutical companies and healthcare providers seeking advanced cancer treatments. The firm's R&D efforts target the biotechnology sector, specifically oncology applications. Curocell Inc's business model centers on creating innovative CAR-T therapies that address unmet medical needs in cancer care. The company's research and development activities are directed at enhancing the efficacy and safety of CAR-T treatments, which are sold to pharmaceutical firms for further development and distribution. The firm's products are positioned within the biotechnology industry, catering to the growing demand for targeted cancer therapies. The company's revenue streams come from the sale of its developed CAR-T technologies to pharmaceutical partners. These partnerships enable the commercialization of Curocell's innovations in the global oncology market. Curocell Inc operates within the biotechnology sector, specifically focusing on the development of next-generation CAR-T therapies for cancer patients. Curocell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Curocell stock

Free Cash Flow per Share of Curocell is -2,138.16 KRW in 2025.

Free Cash Flow per Share of Curocell changed from -2,086.85 KRW to -2,138.16 KRW, representing a 2.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Curocell since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Curocell

All Key Metrics — Curocell